Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE recommends rheumatoid arthritis drug for approval

  • 1 Comment

Rheumatoid arthritis patients will be able to try a powerful new treatment for free after the NHS struck a cost-cutting deal with its manufacturer.

Under the patient access scheme, agreed with NICE, the drugm called Cimzia, will be free to the NHS for the first three months of a patient’s treatment.

If the patient responds favourably the NHS will cover the cost of continuing the drug, which is produced by UCB.

The drug, whose generic name is certolizumab pegol, is the first NICE has recommended for approval for rheumatoid arthritis for more than two years.

Clinical trials showed it eased rheumatoid arthritis symptoms such as fatigue, joint stiffness, weight loss and flu-like symptoms for up to two years, but NICE originally queried whether the medication was cost-effective enough to be provided on the NHS.

Professor Peter Taylor from Imperial College London said: “This is an important new treatment option for people with rheumatoid arthritis, and it’s exciting that it is now available on the NHS.”

  • 1 Comment

Readers' comments (1)

  • i think that will be a big relief to those suffering from the disease condition.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs